Gabapentin Tablet
Product Images NDC 58118-1167

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 58118-1167). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 600mg Tablets 30ct Blister Card (600mg 100s)

Label for Gabapentin 600 mg tablets by Clinical Solutions Wholesale. The label includes NDC 58118-0166-8, a quantity of 30 tablets, and manufacturer information for Camber Pharmaceuticals in Piscataway, NJ. Additional details include lot number SAMPLE123, batch number SAMPLE456, and expiration date April 2025.*

FDA Label Image

Gabapentin 600mg Tablets 30ct Blister Card (800 mg 100s)

Label for Gabapentin 800 mg oral tablets showing Clinical Solutions Wholesale as the labeler. The package contains 30 tablets. It includes manufacturing details by Camber Pharmaceuticals, Piscataway, NJ, and indicates the lot number, expiration date of April 2025, and barcode information.*

FDA Label Image

Sideeffects (Sideeffects)

A partial text panel listing potential side effects or symptoms associated with gabapentin, including lack of coordination, viral infection, difficulty with speaking, tremor, swelling typically of legs and feet, feeling tired, fever, feeling drowsy, nausea and vomiting, jerky movements, difficulty with coordination, double vision, and unusual eye movement.*

FDA Label Image

Table-1 (Table1)

A table titled "Gabapentin Dosage Based on Renal Function" displaying dosing recommendations based on creatinine clearance levels (mL/min). It details total daily dose ranges (mg/day), dose regimens (mg) at various frequency levels (e.g., 300 TID, 400 BID), and post-hemodialysis supplemental doses (mg). Notes clarify dose adjustments for patients with creatinine clearance below 15 mL/min and hemodialysis considerations.*

FDA Label Image

Table-2 (Table2)

A data table titled 'TABLE 2 Risk by Indication for Antiepileptic Drugs in the Pooled Analysis' listing risk metrics for placebo and drug patients across three indications: Epilepsy, Psychiatric, and Other. The table includes events per 1,000 patients, relative risk, and risk difference values for each indication and totals.*

FDA Label Image

Table-3 (Table3)

Table presenting adverse reactions reported in pooled placebo-controlled trials for Gabapentin in postherpetic neuralgia, comparing the percentage incidence of various side effects across body systems for Gabapentin (N=336) and placebo (N=227). Categories include body as a whole, digestive system, metabolic and nutritional disorders, nervous system, respiratory system, and special senses, with detailed percentages for each listed adverse reaction.*

FDA Label Image

Table-4 (Table4)

Table presenting adverse reactions from pooled placebo-controlled add-on trials in epilepsy patients aged over 12, comparing Gabapentin (N=543) and placebo (N=378). It categorizes adverse reactions by body system (e.g., nervous system, digestive, respiratory) with corresponding percentage incidences for each treatment group.*

FDA Label Image

Table-5 (Table5)

Data table titled 'Adverse Reactions in a Placebo-Controlled Add-On Trial in Pediatric Epilepsy Patients Age 3 to 12 Years,' comparing the percentage of patients experiencing various adverse reactions between Gabapentin (N=119) and placebo (N=128) groups across body systems including body as a whole, digestive, nervous, and respiratory systems.*

FDA Label Image

Table-6 (Table6)

A data table titled 'Controlled PHN Studies: Duration, Dosages, and Number of Patients,' presenting two studies with durations of 8 weeks and 7 weeks. It shows target gabapentin doses in mg/day (3600, 1800, 2400) and the number of patients receiving gabapentin and placebo in each study as well as totals.*

FDA Label Image

Clcr (Clcr)

An illustration showing the formula for creatinine clearance (CLCr), calculated based on age in years, weight in kilograms, and serum creatinine in mg/dL, with an adjustment multiplying by 0.85 for female patients.*

FDA Label Image

Figure-1 (Figure1)

Line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores on the vertical axis and weeks on the horizontal axis. Two lines compare placebo and Gabapentin (3600 mg/day) over an 8-week period including a 4-week dose titration and 4-week fixed dose period. Gabapentin shows a decline in mean pain scores over time compared to placebo.*

FDA Label Image

Figure-2 (Figure2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2,' depicting mean pain scores over 7 weeks. The x-axis represents weeks (Baseline to Week 7) and the y-axis shows mean pain scores (0 to 10). Three lines compare Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure-3 (Figure3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) treatments across two studies. Study 1 shows 12% for placebo and 29% for gabapentin 3600 mg. Study 2 shows 14% for placebo, 32% for gabapentin 1800 mg, and 34% for gabapentin 2400 mg, with significance levels indicated by asterisks.*

FDA Label Image

Figure-4 (Figure4)

A scatter plot chart titled 'Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study' showing the response percentage difference by daily dose in mg (600 to 1800) for three studies labeled a, b, and c. The y-axis represents the difference in percentage, ranging from 2% to 22%, and the x-axis shows daily doses in mg. Different colored squares indicate study data points for responder rates at each dose level.*

FDA Label Image

Struc (Struct)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to a carbon with an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.